عربي Español Русский Français 简体中文

Subunit Vaccine Against COVID-19 Approved for Clinical Trials

2020/03/17

A team of researchers from the Academy of Military Medical Sciences of the Academy of Military Sciences, headed by Academician Chen Wei, have been focusing on producing urgently needed vaccines against COVID-19 ever since they arrived in Wuhan. At 20:18 on 16 March, a subunit vaccine they developed was put to clinical trials after approval.

Partnering with a leading local firm and building on its successful experience in developing vaccine for Ebola, Chen's team has worked around the clock after arriving in Wuhan on 26 January to conduct pharmaceutical, pharmacodynamic, pharmacological, and toxicological research on a subunit vaccine. It had since completed vaccine design, recombinant virus seed development, and GMP production and preparation, as well as third-party vaccine safety and efficacy evaluation and quality verification.

On the evening of 16 March, Chen's team received approval to start clinical trials of the vaccine after passing the review and evaluation required for clinical trial registration.

Suggest to a friend
Print